BETH ISRAEL LAHEY HEALTH PHARMACY INC (EIN 822526816) - Form 990 Financial Analysis & Trantor Score

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2017

Legal Domicile

Principal Officer

KEVIN TABB MD

Phone

7813526600

Tax Period

2023-10-01 to 2024-09-30

BETH ISRAEL LAHEY HEALTH PHARMACY INC, founded in 2017, is a major nonprofit in the Health Care sector that reported $292.5M in total revenue in fiscal year 2023. Revenue surged 83% from the prior year, signaling strong growth momentum. Expenses of $277.5M left a modest 5% surplus.

Mission

FROM TIME TO TIME AND UNDER CERTAIN CIRCUMSTANCES, BETH ISRAEL LAHEY HEALTH PHARMACY, INC. OR ONE OF IT'S AFFILIATES MAY CHOOSE TO GROSS-UP A PAYMENT TO MAKE THE EMPLOYEE WHOLE FROM A TAX PERSPECTIVE. AS EXPLAINED FURTHER BELOW, ACROSS BILH THESE SITUATIONS ARE REVIEWED ON A CASE-BY-CASE BASIS AND THE COST OF ANY GROSS-UP IS CONSIDERED WHEN REVIEWING AN EMPLOYEE'S OVERALL COMPENSATION PACKAGE FOR REASONABLENESS. EXAMPLES OF THE TYPES OF EXPENSES WHICH MAY FALL INTO THIS CATEGORY ARE REIMBURSEMENT FOR RELOCATION AND TEMPORARY HOUSING. HOUSING ALLOWANCES WERE PROVIDED TO ONE OFFICER AND ONE KEY EMPLOYEE DURING THE YEAR. THIS BENEFIT WAS TREATED AS PART OF THEIR TAXABLE COMPENSATION.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2023)

Revenue Breakdown

Contributions & Grants $0

Program Service Revenue $292,456,573

Investment Income $0

Other Revenue $0

TOTAL REVENUE $292,456,573

Expense Breakdown

Grants Paid $0

Salaries & Benefits $44,960,122

Fundraising Expenses $0

Program Expenses $277,400,935

Other Expenses $232,498,386

TOTAL EXPENSES $277,458,508

Year-over-Year Comparison

	2023	2022	Change
Revenue	$292,456,573	$159,860,880	+0.8%
Expenses	$277,458,508	$161,547,522	+0.7%
Net Income	$14,998,065	$-1,686,642	-9.9%

Key Indicators

✗ Grants to Organizations ✗ Grants to Individuals ✓ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✗ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

N/A

Volunteers

N/A

Governance Policies

✓ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

⚠ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✓ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

$11,043,618

Total Directors

$9,336,973

Key Employees

$1,596,542

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
ROWAN MICHAEL	TTEE(EXO)(CEO DESIG)EVP HOS&AMB BILH	1.00	Director	$0	$2,401,778	$4,703,895
FIELDS MD ROBERT	CHAIR&TTEE (CHIEF CLIN OFF, BILH)	1.00	Officer Director	$0	$31,658	$1,281,307
DEJESUS JESS	PRES/TTEE (EX-OFF); CHIEF PHARM OFF	55.00	Officer Director	$677,483	$232,173	$909,656
FERNANDEZ RICHARD	TRUSTEE	1.00	Director	$0	$46,810	$670,099
FRANCIOLI CARL	TTEE (CFO, BIDMC)	1.00	Director	$0	$36,098	$600,547
DEVITA NICOLE	TTEE; COO BILH PERFORMANCE NETWORK	1.00	Director	$0	$29,609	$580,748
JONES TINA	ASSTTREAS&TEE (CFO PHARM/DIVERS SVCS	55.00	Officer Director	$421,727	$29,173	$450,900
BEAUMIER MBACPAMHA GREGORY	TTEE (CHIEF FINANCIAL OFFICER, NHC)	1.00	Director	$0	$12,239	$139,821
HORWITZ-WILLIS NATE	TRUSTEE	1.00	Director	$0	$0	$0
TABB MD KEVIN	CEO (EX-OFF) (CEO, BILH)	1.00	Officer	$0	$1,097,028	$5,410,415
RIOS CINDY	TREAS (EX-OFF) (EXEC VP & CFO, BILH)	1.00	Officer	$0	$217,736	$1,689,163
KATZ ESQ JAMIE	CLERK (EX-OFF); GENERAL COUNSEL BILH	1.00	Officer	$0	$32,002	$1,302,177
GILRCHRIST NEIL	VP, PHARMACY OPERATIONS	55.00	Key Emp	$371,858	$36,258	$408,116
MARSHALL JOHN	VICE PRESIDENT, CLINICAL PHARMACY	55.00	Key Emp	$359,800	$43,921	$403,721
ZEMLER WU SHERMAN	VP PHARM STRAT & BUS DEV, BILH PHARM	55.00	Key Emp	$367,817	$35,235	$403,052
SINNADURAI SINTHUSAN	VP PHARMACY BENEFITS MANAGER	55.00	Key Emp	$366,897	$14,756	$381,653
VIOLETTE HOPE	AVP, REGULATORY AND COMPLIANCE	55.00	Highest	$279,849	$34,494	$314,343
PATEL PARTH	DIRECTOR, PHARMACY DATA ANALYTICS	55.00	Highest	$256,105	$39,290	$295,395
CATTANEO LUCA	DIRECTOR SPECIALTY PHARMACY	55.00	Highest	$206,912	$40,573	$247,485
LECH TARA	DIR, PHARMACY ANTICOAGULATION SVCS	55.00	Highest	$192,398	$21,935	$214,333
BORNSTEIN JAY	DIRECTOR, PHARMACY SUPPLY CHAIN	55.00	Highest	$195,862	$6,708	$202,570
CULLEN MICHAEL R	FRMR TTEE; CFO/SVP FINANCE, BIDMC	0.00		$0	$0	$259,620

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2024	$292,456,573	$277,458,508	$119,708,984	$14,998,065
2023	$159,860,880	$161,547,522	$80,133,209	$-1,686,642
2022	$84,118,749	$82,332,272	$25,263,389	$1,786,477
2021	$210,599,852	$210,599,852	$32,825,089	No data
2020	$158,475,092	$158,475,092	$3,872,896	No data
2019	$78,576,836	$78,576,836	$13,244,702	No data
2018	$15,492,649	$15,492,649	$2,399,844	No data

BETH ISRAEL LAHEY HEALTH PHARMACY INC